Bispecific Antibody Lanscape: Evolution, Breakthroughs, and Prospects

From "Single-Target Era" to "Dual-Mechanism Era"

As PD-1 monoclonal antibodies (mAbs) enter an increasingly crowded market, antibody drug development is shifting from single-mechanism therapies to multi-mechanism strategies. While mAbs have transformed the treatment of cancer, autoimmune, and infectious diseases, the limitations of single-target therapies are becoming more apparent. Tumors can develop resistance through alternative signaling pathways, and complex immune or inflammatory networks are often difficult to control with one mechanism alone.

Against this backdrop, bispecific antibodies (bsAbs) have emerged as a major next-generation therapeutic platform. By simultaneously binding two antigens or epitopes, bsAbs enable dual-mechanism synergy within a single molecule, offering greater flexibility and stronger therapeutic potential than traditional mAbs.

https://doi.org/10.1038/s41573-019-0028-1

Mechanism of action of bsAbs

Development Trajectory: From Concept to Industrial Boom

The development of bsAbs has followed a classic trajectory of "high expectations, setbacks, and resurgence." The concept was first proposed in the 1960s, with early research efforts beginning in the 1980s. However, progress remained slow for decades due to immature antibody engineering technologies, including heavy/light chain mispairing, poor expression efficiency, limited stability, and short half-life.

The field advanced significantly after 2010 with the maturation of engineering platforms such as KiH, CrossMAb, DuoBody, and XmAb, which improved chain pairing accuracy, pharmacokinetics, and manufacturability. In 2014, the approval of the first T-cell engager (TCE), Blinatumomab (CD3×CD19), marked the commercial breakthrough of bsAbs. In 2017, Emicizumab (FIXa×FX) achieved major success in hemophilia, further validating the clinical value of bsAbs beyond oncology.

Since then, both approved products and clinical pipelines have expanded rapidly, with especially strong acceleration between 2022 and 2025. BsAbs have evolved from an experimental innovation into a core segment of global biologics R&D. Industry competition is also shifting from simply "making bispecifics" to optimizing mechanism design, safety, and commercialization capabilities.

Top 10 multispecific antibody deals in 2025

https://doi.org/10.1038/d43747-025-00111-4

Expanding Therapeutic Frontiers of BsAbs

Hematologic Malignancies Lead the Way

Oncology remains the dominant application area for bsAbs, with hematologic malignancies representing the most mature segment. TCE platforms have demonstrated remarkable efficacy in acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. Products such as Mosunetuzumab (CD20×CD3) and Teclistamab (BCMA×CD3) are driving bsAbs from late-line settings toward earlier lines of therapy.

Breaking Through in Solid Tumors

Compared with hematologic cancers, solid tumors present greater challenges, including high tumor heterogeneity, immunosuppressive microenvironments, and limited tissue penetration. In recent years, several bsAbs have achieved important breakthroughs in solid tumors. Cadonilimab (PD-1×CTLA-4), based on dual immune checkpoint blockade, became one of the first approved products in gastric and cervical cancers. Tarlatamab (DLL3×CD3) has shown promise in overcoming long-standing treatment barriers in small-cell lung cancer, while Tebentafusp (gp100×CD3) delivered unprecedented survival benefits in uveal melanoma.

Expanding into Autoimmune, Ophthalmic, and Rare Diseases

Beyond oncology, bsAbs are rapidly expanding into autoimmune diseases, ophthalmology, and infectious diseases. Telitacicept (BLyS×APRIL) has been approved in China for systemic lupus erythematosus, representing a major milestone for autoimmune bsAbs. Faricimab (Ang-2×VEGF-A) has been approved for wet age-related macular degeneration, while Emicizumab has become a landmark therapy in hemophilia. In parallel, bsAb programs targeting HIV and COVID-19 continue to advance, further broadening the therapeutic scope of the modality. BsAbs are increasingly evolving from a cancer immunotherapy strategy into a versatile platform technology across multiple disease areas.

https://doi.org/10.1016/j.intimp.2026.116747

Visual representation of BsAbs technology landscape

Key Challenges in Bispecific Antibody Development

Despite rapid progress, several critical challenges remain before bsAbs can achieve full maturity. First, CMC and manufacturing complexity remain major barriers. Compared with conventional mAbs, bsAbs have more sophisticated structures that require precise chain pairing while minimizing aggregation, heterogeneity, and stability risks. As a result, process development and quality control are significantly more demanding.

Second, safety management remains a major concern in clinical development, particularly for TCEs, which are associated with cytokine release syndrome (CRS) and neurotoxicity. Achieving stronger immune activation while maintaining a manageable safety profile remains a key focus of current R&D efforts.

In addition, as global pipelines expand rapidly, the industry is entering an era of increasing homogenization. Long-term competitiveness will depend not only on dual-target design itself, but also on mechanism innovation, indication strategy, safety optimization, and commercialization strength. Competition in the bsAb field is gradually shifting from "platform competition" to "clinical value competition."

Conclusion: Bispecific Antibodies Are Reshaping the Next Generation of Biologics

By 2026, bsAbs are no longer merely a hot concept; they have entered a phase of clinical validation and accelerated commercialization. From early success in hematologic malignancies to continued expansion in solid tumors and growing applications in autoimmune and other non-oncology diseases, bsAbs are evolving into a major therapeutic platform spanning multiple disease areas.

Looking ahead, advances in AI-assisted antibody design, novel delivery technologies, and Fc engineering are expected to drive the next generation of bsAbs toward greater efficacy, improved safety, and enhanced manufacturability.

ACRO Comprehensive Solutions for Bispecific Antibody Development

In line with these trends, ACROBiosystems provides comprehensive solutions covering the full bsAbs R&D process. Our portfolio includes high-consistency target proteins, functional cell lines, application-specific assay kits, and customization and analytical services. These tools support key stages from early target discovery and validation, candidate screening and functional evaluation, to CMC development and quality control, helping accelerate the development and translation of innovative bsAb therapies.

FAQ

Q: What is a bispecific antibody (bsAb)?

A: Bispecific antibodies (bsAbs) are engineered antibodies designed to bind two different antigens or epitopes simultaneously. They enable dual-target engagement within a single molecule, allowing functions such as immune cell redirection or simultaneous pathway blockade, which cannot be achieved by monoclonal antibodies.

Q: How do bispecific antibodies work in cancer therapy?

A: Most therapeutic bsAbs function by physically bringing immune effector cells (e.g., T cells via CD3) into proximity with tumor cells, forming an immune synapse that triggers targeted tumor cell killing. This mechanism is widely used in T-cell engagers (TCEs) for hematologic malignancies and emerging solid tumor therapies.

Q: What are the main engineering challenges in bsAb development?

A: Key challenges include heavy/light chain mispairing, protein aggregation, structural stability, and manufacturing consistency. Advanced platforms such as Knobs-into-Holes (KiH), CrossMAb, and DuoBody are commonly used to improve correct chain pairing and developable properties.

Q: What are the key factors affecting batch-to-batch consistency in bsAb CMC development?

A: Batch consistency is influenced by chain mispairing, post-translational modifications, aggregation levels, and purification efficiency. Compared with monoclonal antibodies, bsAbs require more stringent process control and analytical characterization to ensure structural and functional consistency.

Q: What tools are needed for bispecific antibody research and development?

A: bsAb development requires high-quality recombinant proteins, functional cell systems, and binding or potency assays for target validation and candidate screening. These tools are essential across discovery, preclinical evaluation, and CMC development stages.

Solutions from ACROBiosystems support bsAb research with recombinant protein, assay kits, and cell lines to accelerate antibody discovery and development workflows.

References

1. Labrijn A F, Janmaat M L, Reichert J M, et al. Bispecific antibodies: a mechanistic review of the pipeline[J]. Nature reviews Drug discovery, 2019, 18(8): 585-608. https://doi.org/10.1038/s41573-019-0028-1

2. Marshall A. The year of the bispecific in oncology and beyond[J]. Endocrinology, 400: 450. https://doi.org/10.1038/d43747-025-00111-4

3. Pandey A, Wankhade S, Murthy A, et al. The rise of bispecific antibodies for dual targeting, singular impact: technology and clinical advancements[J]. International Immunopharmacology, 2026, 181: 116747. https://doi.org/10.1016/j.intimp.2026.116747